Manning Paul B
SEC CIK 1494695 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| LQDA | Liquidia Corp | Dir | 475.5K | $7.00M | $31.74M | 11 | 2022-03-31 | 2026-06-16 |
| CADL | Candel Therapeutics, Inc. | Dir, 10% | 2.76M | $23.91M | — | 7 | 2021-07-27 | 2026-02-23 |
| VRCA | Verrica Pharmaceuticals Inc. | Dir, 10% | 3.96M | $28.97M | — | 9 | 2021-12-02 | 2025-11-25 |
| TSHA | Taysha Gene Therapies, Inc. | Dir, 10% | 2.84M | $24.90M | — | 9 | 2021-11-23 | 2025-05-30 |
| ABOS | Acumen Pharmaceuticals, Inc. | 10% | 658.0K | $5.00M | — | 2 | 2021-07-06 | 2021-07-06 |
Most active insiders at LQDA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Bloch Stephen M | Dir | — | $118.66M |
| 2 | JEFFS ROGER | CEO, Dir | — | $31.72M |
| 3 | Kaseta Michael | CFO, COO | — | $15.97M |
| 4 | Manning Paul B | Dir | — | $12.78M |
| 5 | Saggar Rajeev | Chief Medical Off | — | $11.16M |
| 6 | Adair Jason | Chief Business Off | — | $7.77M |
| 7 | Moomaw Scott | Chief Commercial Off | — | $5.52M |
| 8 | Rielly-Gauvin Katherine | Dir | — | $4.09M |
| 9 | Krepp Sarah | Chief Human Resource Off | — | $3.69M |
| 10 | SINGH RAMAN | Dir | — | $3.67M |
Transactions 38
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-18 16:15 | 2026-06-16 | LQDA | Liquidia Corp | Manning Paul B | Dir | A - Grant | $0.00 | +5,882 | 475.5K | +1% | $0 | |
| MI | 2026-06-08 16:41 | 2026-06-04 | LQDA | Liquidia Corp | Manning Paul B | Dir | S - Sale | $63.91 | -200.0K | 798.3K | -20% | -$12.78M |
| I | 2026-02-26 | 2026-02-23 | CADL | Candel Therapeutics, Inc. | Manning Paul B | Dir | P - Purchase | $5.45 | +550.5K | 2.76M | +25% | +$3.00M |
| I | 2026-02-12 | 2026-02-11 | LQDA | Liquidia Corp | Manning Paul B | Dir | J - Other | $42.63 | -55.1K | 0 | -100% | -$2.35M |
| 2026-02-12 | 2026-02-11 | LQDA | Liquidia Corp | Manning Paul B | Dir | J - Other | $42.63 | +55.1K | 469.6K | +13% | +$2.35M | |
| D | 2025-11-25 | 2025-11-25 | VRCA | Verrica Pharmaceuticals Inc. | Manning Paul B | Dir, 10% | P - Purchase | $4.24 | +1.38M | 3.96M | +53% | +$5.83M |
| DI | 2025-11-25 | 2025-11-25 | VRCA | Verrica Pharmaceuticals Inc. | Manning Paul B | Dir, 10% | P - Purchase | $4.24 | +2.75M | 3.35M | +460% | +$11.66M |
| MI | 2025-09-02 | 2025-08-28+ | LQDA | Liquidia Corp | Manning Paul B | Dir | S - Sale | $28.26 | -670.8K | 759.1K | -47% | -$18.96M |
| I | 2025-06-26 | 2025-06-25 | CADL | Candel Therapeutics, Inc. | Manning Paul B | Dir | A - Grant | $4.67 | +1.07M | 2.21M | +94% | +$5.00M |
| 2025-06-20 | 2025-06-17 | LQDA | Liquidia Corp | Manning Paul B | Dir | A - Grant | $0.00 | +18.4K | 38.8K | +90% | $0 | |
| I | 2025-06-03 | 2025-05-30 | TSHA | Taysha Gene Therapies, Inc. | Manning Paul B | 10% | P - Purchase | $2.75 | +750.0K | 2.84M | +36% | +$2.06M |
| MI | 2024-12-18 | 2024-12-16 | CADL | Candel Therapeutics, Inc. | Manning Paul B | Dir | P - Purchase | $6.00 | +1.25M | 1.30M | +2,325% | +$7.50M |
| DI | 2024-11-26 | 2024-11-22 | VRCA | Verrica Pharmaceuticals Inc. | Manning Paul B | Dir, 10% | P - Purchase | — | +4.49M | 5.98M | +303% | — |
| D | 2024-11-26 | 2024-11-22 | VRCA | Verrica Pharmaceuticals Inc. | Manning Paul B | Dir, 10% | P - Purchase | — | +18.43M | 26.28M | +235% | — |
| D | 2024-11-26 | 2024-11-26 | VRCA | Verrica Pharmaceuticals Inc. | Manning Paul B | Dir, 10% | G - Gift | $0.00 | -450.0K | 25.83M | -2% | $0 |
| MI | 2024-09-23 | 2024-09-19 | VRCA | Verrica Pharmaceuticals Inc. | Manning Paul B | Dir, 10% | G - Gift | $0.00 | +0.00 | 0 | New | $0 |
| I | 2024-09-16 | 2024-09-12 | LQDA | Liquidia Corp | Manning Paul B | Dir | P - Purchase | $8.90 | +337.1K | 816.3K | +70% | +$3.00M |
| 2024-07-01 | 2024-06-27 | TSHA | Taysha Gene Therapies, Inc. | Manning Paul B | 10% | P - Purchase | $2.25 | +1.33M | 1.33M | New | +$3.00M | |
| 2024-06-24 | 2024-06-20 | LQDA | Liquidia Corp | Manning Paul B | Dir | A - Grant | $0.00 | +20.4K | 299.7K | +7% | $0 | |
| 2023-12-18 | 2023-12-14 | LQDA | Liquidia Corp | Manning Paul B | Dir | P - Purchase | $7.16 | +279.3K | 279.3K | New | +$2.00M | |
| I | 2023-11-20 | 2023-11-17 | TSHA | Taysha Gene Therapies, Inc. | Manning Paul B | 10% | P - Purchase | $1.63 | +100.0K | 16.57M | +0.6% | +$163.0K |
| I | 2023-08-16 | 2023-08-16 | TSHA | Taysha Gene Therapies, Inc. | Manning Paul B | 10% | P - Purchase | $0.9 | +16.47M | 16.47M | New | +$14.82M |
| 2023-07-24 | 2023-07-24 | VRCA | Verrica Pharmaceuticals Inc. | Manning Paul B | Dir, 10% | P - Purchase | $5.02 | +200.0K | 7.85M | +3% | +$1.00M | |
| 2022-11-02 | 2022-10-31 | TSHA | Taysha Gene Therapies, Inc. | Manning Paul B | Dir, 10% | P - Purchase | $2.00 | +1.50M | 1.64M | +1,055% | +$3.00M | |
| 2022-07-05 | 2022-07-05 | VRCA | Verrica Pharmaceuticals Inc. | Manning Paul B | Dir, 10% | P - Purchase | $2.10 | +4.76M | 13.65M | +54% | +$10.00M | |
| I | 2022-04-20 | 2022-03-31 | LQDA | Liquidia Corp | Manning Paul B | Dir | A - Grant | $0.00 | +435.7K | 435.7K | New | $0 |
| 2022-04-19 | 2022-04-18 | LQDA | Liquidia Corp | Manning Paul B | Dir | P - Purchase | $5.10 | +392.2K | 392.2K | New | +$2.00M | |
| MI | 2022-02-04 | 2022-02-02+ | TSHA | Taysha Gene Therapies, Inc. | Manning Paul B | Dir, 10% | P - Purchase | $7.79 | +93.6K | 2.07M | +5% | +$729.1K |
| M | 2022-02-04 | 2022-02-02+ | TSHA | Taysha Gene Therapies, Inc. | Manning Paul B | Dir, 10% | P - Purchase | $7.80 | +108.0K | 92.2K | New | +$842.7K |
| M | 2021-12-06 | 2021-12-02+ | VRCA | Verrica Pharmaceuticals Inc. | Manning Paul B | Dir, 10% | P - Purchase | $9.36 | +50.0K | 8.15M | +0.6% | +$467.9K |
| 2021-11-29 | 2021-11-24 | TSHA | Taysha Gene Therapies, Inc. | Manning Paul B | Dir, 10% | P - Purchase | $13.19 | +2,202 | 34.2K | +7% | +$29.0K | |
| 2021-11-24 | 2021-11-23 | TSHA | Taysha Gene Therapies, Inc. | Manning Paul B | Dir, 10% | P - Purchase | $12.54 | +20.0K | 32.0K | +167% | +$250.8K | |
| DMAI | 2021-08-04 | 2021-07-29 | CADL | Candel Therapeutics, Inc. | Manning Paul B | Dir, 10% | C - Cnv Deriv | — | +1.23M | 679.2K | New | — |
| DA | 2021-08-04 | 2021-07-29 | CADL | Candel Therapeutics, Inc. | Manning Paul B | Dir, 10% | P - Purchase | $8.00 | +1.62M | 1.68M | +2,902% | +$13.00M |
| DMI | 2021-08-02 | 2021-07-29 | CADL | Candel Therapeutics, Inc. | Manning Paul B | Dir | C - Cnv Deriv | — | +1.23M | 553.8K | New | — |
| M | 2021-07-29 | 2021-07-27+ | CADL | Candel Therapeutics, Inc. | Manning Paul B | Dir | P - Purchase | $7.34 | +56.0K | 56.0K | New | +$411.0K |
| DMI | 2021-07-08 | 2021-07-06 | ABOS | Acumen Pharmaceuticals, Inc. | Manning Paul B | 10% | C - Cnv Deriv | — | +3.61M | 658.0K | New | — |
| DI | 2021-07-08 | 2021-07-06 | ABOS | Acumen Pharmaceuticals, Inc. | Manning Paul B | 10% | P - Purchase | $16.00 | +312.5K | 3.35M | +10% | +$5.00M |
Purchase Sale Sale after option exercise All abbreviations